Home > Back to Publisher > Report Information

Cannabinoid Market Forecasts & Analysis to 2012

Visiongain
March 22, 2007
199 Pages - SKU: VSG1491414

Abstract Table of Contents Related Reports

With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the cannabinoid market continues to grow. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster is now a certainty.

4 drugs already available:

Marinol® (dronabinol)
Cesamet® (nabilone)
Sativex ® (oral cannabis extract spray)
Acomplia® (Rimonabant)

With indications for the control of chemotherapy-induced nausea and vomiting, Marinol has additional approval as an appetite stimulant to treat anorexia associated with HIV/AIDS.

The worlds first whole-cannabis plant extract, Sativex was developed by GW. The approval of Sativex upon the Canadian neuropathic pain associated Multiple Sclerosis market was in 2005, Sativex is expected to help the market with its additional indications and its introduction to Europe and the US.

The profile of the market is set to be raised considerably due to the launch of Rimonabant by Sanofi-Aventis for obesity. The fact that the drug is imminent in the US and EU, will further push its success to blockbuster status. With such important developments within the cannabinoid market, cannabinoids become pharmaceutical products rather than political products and will further ensure increased R&D efforts into this market. Major Pharma will not sit around and watch blockbusters being created withough them wanting to be part of the success. Will you be part of the success?

Visiongain values todays cannabinoid market at $0.7095 billion. This has grown 45.5% from 2006's revenues of $0.3867 billion. Visiongain predicts the growth of the market will continue over the forecast period to 2012. Our accurate projections within this report, suggest excellent prospects for the cannabinoid market as a whole.

Designed as a critical business aid, Cannabinoids Market Forecasts & Analysis to 2012 provides the industry's leading evaluation of the market. Now in its 2nd edition, the report focuses on the following aspects:

Potential Cannabinoid Therapies
The Worldwide Cannabinoid Market- Current and Future Products
Pipeline Cannabinoid Products
Company Information
Market Activity
Forecasts to 2012
Regulatory Issues of Cannabinoids and Medically Approved Cannabis in the eight Major Markets
Alternative therapeautic areas - maximising revenue through alternative indications

The report provides in-depth market analysis for current and potential products. The report extensively identifies cannabinoid drugs market potential by analysing the latest clinical trial research and highlighting new indications. The study also assesses the challenges faced by potential companies. Attitudes to cannabinoids are changing - a blockbuster is set to happen.

Why You Must Buy This Report:

This 190+ paged report features 26 tables, 42 graphs and figures, news, insights, the very latest developments and an in depth review of the cannabinoids market with up to date analysis. This report is a vital addition to gaining an understanding of this growing sector of the pharmaceutical market, and will give your company 'the edge' over your competitors. You can not afford to be without this latest report from visiongain.

Five key questions this report answers are:

What is the market potential for cannabinoids treating various diseases?
What latest clinical trials/experimental research has been performed to develop cannabinoids for therapeutic uses?
What is the global cannabinoid market value of today and the future worth?
How the cannabinoid market will gain blockbuster status and why?
What are the regulatory issues surrounding cannabinoids and medicinal cannabis use in the eight major markets?

Methodology:

The information contained in this report is from primary industry sources. This includes one-on-one interviews with companies, with governmental bodies and academic insitutions. Analysis has also been drawn from company reports, whether annual financial returns or white papers.

Unique benefits to you when you order this report:

Immediate access through our exclusive Reading Room
You can access your report whichever country you are in without using harddrive space
Primary research throughout. You will not find this information anywhere else
Report stored in your reading room for ever
Full searchable report when you buy the company or corporate editions
Copies can be printed off for offline reading
Packed with charts, analysis, figures, graphs and tables

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Additional Information

Organisations Listed
AFT
Alcasynn Pharmaceuticals
AOP
Almirall Prodesfarma
AstraZeneca
Atlantic Technology Venture Inc.
Bayer Healthcare
Biogen Idec
BMS
BTG
Cambridge Laboratories
Cedarburg Pharmaceuticals
Celltech
Chiesl
Delta 9 Pharmaceuticals
Dov Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
GSK
GW Pharmaceuticals
MakScientific
Medifront
Medilink
MegaPharm
Metaphore Pharmaceuticals
Nektar Therapeutics
Novartis
Orphan Australia
Otsuka Pharmaceuticals
Par Pharmaceuticals
Pfizer
Pharmos
Prestwick Pharmaceuticals
Sanofi-Aventis
Serb Laboratories
Serono
Schering-AG
Solvay Pharmaceuticals
Teva Pharmaceuticals
THC Pharmaceuticals
Unimed Pharmaceuticals
Valeant Pharmaceuticals
Yissum Research Development Co.

Executive Summary: E.1 Introduction to the Cannabinoids Market; E.2 Cannabinoid Potential Therapeutic Areas; E.3 GW Pharmaceuticals: The Cannabinoid Company
Chapter 1. Introduction: 1.1 Purpose of Report; 1.2 Objectives of Report; 1.3 Scope of Report
Chapter 2. Introduction to Cannabinoids: 2.1 A Historical Background to Cannabinoid Therapies; 2.2 An Overview of Cannabinoids; 2.3 How do Cannabinoids Differ to Cannabis?; 2.4 An Overview of Cannabinoid Receptors; 2.5 Marinol, Nabilone, Sativex & Rimonabant: The four Medicinal Cannabinoids of Importance; 2.6 The Therapeutic Potential of Cannabinoids; 2.7 Major Questions Regarding Cannabinoids
Chapter 3. Potential Cannabinoid Therapies: 3.1 Cannabinoids of Therapeutic Value; 3.2 The Cannabinoid Drugs currently on the Global Market; 3.3 The Potential Clinical Uses of Cannabinoids Overview; 3.4 Cannabinoids and Pain: An Alternative to Opioids?; 3.5 Neurological; 3.6 Cancer; 3.7 Eating Disorders; 3.8 Dysfunction of the Immune System; 3.9 Respiratory; 3.10 Anti Addiction; 3.11 Miscellaneous; 3.12 Visiongain's Prespective of Cannabinoid Therapeutics
Chapter 4. The Worldwide Cannabinoids Market: Current Cannabinoids and Potential Products: 4.1 Overview of Today's Global Cannabinoids Market: A Potential Blockbuster?; 4.2 Total Global Cannabinoid Market; 4.3 Marinol; 4.4 Nabilone; 4.5 Sativex; 4.6 Rimonabant; 4.8 Cannabinoids Potential to Gain Blockbuster Status: Visiongain's Perspective; 4.9 Will Cannabinoids Achieve Blockbuster Status? A Survey of Industry Representatives; 4.10 GW Pharmaceuticals Perspective on Cannabinoids Achieving Blockbuster Status
Chapter 5. Pipeline Cannabinoid Products: 5.1 Introduction to Cannabinoid Companies; 5.2 Impressive Cannabinoids Pipeline; 5.3 Growing Interest of Big Pharmaceuticals in Cannabinoid R&D; 5. 4 Almirall Prodesfarma; 5.5 Atlantic Technology Venture Inc and Indevus; 5.6 Bayer Healthcare AG; 5.7 GW Pharmaceuticals; 5.8 MakScientific/Endo Pharmaceuticals Inc; 5.9 Novartis; 5.10 Par Pharmaceuticals; 5.11 Pharmos Corporation; 5.12 Pfizer; 5.13 Sanofi-Aventis; 5.14 Solvay; 5.15 Valeant Pharmaceuticals; 5.16 Yissum
Chapter 6. Regulatory Issues of Cannabinoids and Medically Approved Cannabis: 6.1 The Politics of Therapeutic Cannabinoid and Cannabis Use; 6.2 The US; 6.3 Canada; 6.4 The UK; 6.5 Japan; 6.6 France; 6.7 Germany; 6.8 Italy; 6.9 Spain
Chapter 7. Conclusion to Cannabinoids: 7.1 A Potential Blockbuster?
List of figures: Figure 2.1 Chemical Structures of the Major Cannabinoids; Figure 4.1 Valeant's Drug Pipeline; Figure 5.1 Indevus's Pipeline
List of graphs: Graph E.1 Total Cannabinoid Market Revenue Forecast ($bn); Graph E.2 Sativex Revenue Forecast ($m); Graph E.3 Rimonabant Revenue Forecast ($bn); Graph 4.1 Revenues of Cannabinoid Market ($m); Graph 4.2 Marinol Revenue Forecast 2006-2012 ($thousands); Graph 4.3 Marinol Percentage Growth; Graph 4.4 Nabilone Revenue Forecast 2006 - 2012 ($); Graph 4.5 Nabilone Percentage Growth; Graph 4.6 Sativex Revenue Forecast 2006 - 2012 ($m); Graph 4.7 Sativex Percentage Growth; Graph 4.8 Rimonabant Revenue Forecast 2006 - 2012 ($bn); Graph 4.9 Investment Banks' Revenue Forecast on Rimonabant ($bn); Graph 5.1 Alimrall Sales (EUm); Graph 5.2 Almirall R&D Costs (EUm); Graph 5.3 Almirall Sales By Region (EUm); Graph 5.4 Bayer Sales (EUm); Graph 5.5 Bayer Net Profit (EUm); Graph 5.6 Bayer R&D Costs (EUm); Graph 5.7 Bayer Regional Sales ($m); Graph 5.8 Novartis Sales ($m); Graph 5.9 Novatis Net Profit ($m); Graph 5.10 Novartis R&D Costs ($m); Graph 5.11 Novartis Sales by Region ($m); Graph 5.12 Par Sales ($ thousands); Graph 5.13 Par Net Profit ($ thousands); Graph 5.14 Par R&D Costs ($m); Graph 5.15 Pfizer Sales ($m); Graph 5.16 Pfizer Net Profit ($m); Graph 5.17 Pfizer R&D Costs ($m); Graph 5.18 Pfizer Sales By Region ($m); Graph 5.19 Sanofi-Aventis Sales (EUm); Graph 5.20 Sanofi-Aventis Net Profit (EUm); Graph 5.21 Sanofi-Aventis R&D Costs (EUm); Graph 5.22 Sanofi-Avenits Sales By Region (EUm); Graph 5.23 Solvay Sales (EUm); Graph 5.24 Solvay Net Profit (EUm); Graph 5.25 Solvay R&D Costs (EUm); Graph 5.26 Solvay Sales By Region (EUm); Graph 5.27 Valeant Sales ($m); Graph 5.28 Valeant Net Profit ($m); Graph 5.29 Valeant R&D Costs ($m); Graph 5.30 Valeant Sales By Region ($m)
List of Tables: Table E.1 Potential Diseases All Cannabinoids May Treat; Table 2.1 The Major Cannabinoids in Cannabis; Table 2.2 Properties of the Major Cannabinoids in Cannabis; Table 2.3 Synthetic Cannabinoids and Their Characteristics; Table 2.4 Potential Therapeutic Areas of Cannabinoid Therapies; Table 2.5 Acute and Chronic Adverse Effects of THC; Table 3.1 Potential Diseases All Cannabinoids May Treat, 2007; Table 3.2 Cannabinoid Clinical Trial Outcomes of Various Diseases; Table 3.3 Background to Diseases in Which Cannabinoids may Have a Use; Table 3.4 The Potential Circumstances for Cannabinoid Use in Pain Control; Table 3.5 Neuropathic Pain Disorders; Table 3.6 Target Patients for Cannabinoid Pain Relief; Table 3.7 Visiongain's Perspective of the Therapeutic Potential of Cannabinoids by Disease, 2007; Table 4.1 Revenues of Cannabinoid Market ($m); Table 4.2 Top Products in the same Therapeutic Area; Table 4.3 Stages of Development; Table 4.4 Countries where Nabilone is Marketed by Cambridge Labs Distribution Partners; Table 4.5 THC Pharma Cannabinoid Catalogue Products, 2007; Table 4.6 Stages of Development; Table 4.7 Stages of Development; Table 4.8 Stages of Development; Table 4.9 Investment Banks' Revenue ($bn); Table 5.1 Endo Sales by Region; Table 5.2 Pfizer CB1 Candidates in R&D, 2007; Table 6.1 Schedule III Benefits of Marinol Compared to Schedule II; Table 6.2 11 US States That Have Legalised Medical Use of Cannabis

Cannabinoid Market Forecasts & Analysis to 2012

Share this report

Other tasks

Research Assistance

Related Markets

Drug Discovery Reports

Free Alert Me service